Explore

Trendline Trendline
Janux Therapeutics Reports Q1 2026 Financial Results and Pipeline Progress

Janux Therapeutics Reports Q1 2026 Financial Results and Pipeline Progress

Janux Therapeutics Reports Q1 2026 Financial Results and Pipeline Progress
Trendline Trendline
Verastem Oncology Reports Financial Results and Initiates New Cancer Trials

Verastem Oncology Reports Financial Results and Initiates New Cancer Trials

Verastem Oncology Reports Financial Results and Initiates New Cancer Trials
Trendline Trendline
Soligenix Reports Financial Results and Strategic Updates Amid Clinical Trial Challenges

Soligenix Reports Financial Results and Strategic Updates Amid Clinical Trial Challenges

Soligenix Reports Financial Results and Strategic Updates Amid Clinical Trial Challenges
Trendline Trendline
Vir Biotechnology Reports Strong Financial Position and Advances in Cancer and Hepatitis Delta Programs

Vir Biotechnology Reports Strong Financial Position and Advances in Cancer and Hepatitis Delta Programs

Vir Biotechnology Reports Strong Financial Position and Advances in Cancer and Hepatitis Delta Programs
Trendline Trendline
Zai Lab Reports Q1 2026 Financial Results and Advances Oncology Pipeline

Zai Lab Reports Q1 2026 Financial Results and Advances Oncology Pipeline

Zai Lab Reports Q1 2026 Financial Results and Advances Oncology Pipeline
Trendline Trendline
AN2 Therapeutics to Engage in 2026 Stifel Virtual Targeted Oncology Forum

AN2 Therapeutics to Engage in 2026 Stifel Virtual Targeted Oncology Forum

AN2 Therapeutics to Engage in 2026 Stifel Virtual Targeted Oncology Forum
Trendline Trendline
BioLife Solutions Reports 25% Revenue Increase in Q1 2026, Strengthening Market Position

BioLife Solutions Reports 25% Revenue Increase in Q1 2026, Strengthening Market Position

BioLife Solutions Reports 25% Revenue Increase in Q1 2026, Strengthening Market Position
Trendline Trendline
EyePoint Reports Increased Losses Amid DURAVYU Phase 3 Trials Progress

EyePoint Reports Increased Losses Amid DURAVYU Phase 3 Trials Progress

EyePoint Reports Increased Losses Amid DURAVYU Phase 3 Trials Progress
Trendline Trendline
Arrowhead Pharmaceuticals Reports Strong Fiscal 2026 Second Quarter Results Amidst Growth Initiatives

Arrowhead Pharmaceuticals Reports Strong Fiscal 2026 Second Quarter Results Amidst Growth Initiatives

Arrowhead Pharmaceuticals Reports Strong Fiscal 2026 Second Quarter Results Amidst Growth Initiatives
Trendline Trendline
NImmune Biopharma Presents Promising Data for IBD Treatment at Digestive Disease Week

NImmune Biopharma Presents Promising Data for IBD Treatment at Digestive Disease Week

NImmune Biopharma Presents Promising Data for IBD Treatment at Digestive Disease Week
Trendline Trendline
Curis to Announce Q1 2026 Financial Results and Host Webcast

Curis to Announce Q1 2026 Financial Results and Host Webcast

Curis to Announce Q1 2026 Financial Results and Host Webcast
Trendline Trendline
Nuvectis Pharma Reports Increased Net Loss in Q1 2026

Nuvectis Pharma Reports Increased Net Loss in Q1 2026

Nuvectis Pharma Reports Increased Net Loss in Q1 2026